InvestorsHub Logo
Followers 11
Posts 1101
Boards Moderated 0
Alias Born 11/21/2016

Re: rstar post# 11607

Thursday, 07/23/2020 11:30:11 AM

Thursday, July 23, 2020 11:30:11 AM

Post# of 42620
I’d have to read all the PIs, side effects, and adverse reactions for all of them. There’s risk with everything, but it’s like investing/gambling, you have to weigh risk vs reward.

But Abbvie has managed to make Humira the biggest drug ever with multiple indications and accounts for 60%+ of their business.

They competed the acquisition of Allergan this year to offset the revenue stream losses they expect when Humira loses its protection and generics come online.

The migraine space now has multiple MABs that have helped people go from 20+ migraine days a month to less than 10,5, or none on some cases.

MABs are definitely a large part of future therapeutic treatments. The biggest aversion is people who don’t want to get a shot every month.

One migraine MAB actually has a 90 day version now so people only have to get an injection every 3 months and only have to go to the Dr every 3 months for it.

All just food for thought.

HGEN ????